In this issue of Blood, Petit et al demonstrate the clinical utility of a genetic classifier combined with end of induction minimal residual disease (MRD) assessment and presenting white blood cell (WBC) count in the effective risk stratification of pediatric patients with T-cell acute lymphoblastic leukemia (T-ALL).1 The integration of these factors allowed the identification of 3 discrete clinical risk groups providing an opportunity for improved treatment allocation.

中文翻译：

---

完善 T-ALL 中的遗传分层

在本期血液杂志中，Petit 等人展示了遗传分类器结合诱导期微小残留病 (MRD) 评估结束和白细胞 (WBC) 计数在儿科 T 细胞患者的有效风险分层中的临床效用急性淋巴细胞白血病 (T-ALL)。1 这些因素的整合允许识别 3 个离散的临床风险组，为改进治疗分配提供机会。